December 24th 2024
With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?
Real Psychiatry 2025
January 17 - 18, 2025
View More
More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Expert Perspectives in the Recognition and Management of Postpartum Depression
View More
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
TEV-'749: An Option to Serve an Important Treatment Gap for Patients With Schizophrenia
October 14th 2024Learn more about the new positive efficacy, safety, tolerability data from the phase 3 SOLARIS trial, which were presented at the 37th Annual European College of Neuropsychopharmacology Congress.
Read More
Poll: Do You Feel Prepared to Prescribe the Newly Approved First-In-Class Muscarinic Agonist?
September 27th 2024The first-in-class muscarinic agonist Cobenfy, formerly known as KarXT, was just approved by the FDA to treat schizophrenia in adults. Are you ready to discuss it with patients and caregivers?
Read More
Twenty Years of Using and Contributing to the Model Curriculum for Psychopharmacology Teachers
September 4th 2024Although the Model Curriculum for Teachers of Psychopharmacology has evolved over 2 decades, it continues to provide practical and easy to use resources for psychiatric educators from leading experts.
Read More
The Safety of Psychostimulants or Atomoxetine for Patients With Psychotic Disorders
Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.
Read More
Treatment Options for the Management of Behavioral and Psychological Symptoms of Dementia
The behavioral and psychological symptoms of dementia contribute significantly to the greater rates morbidity and mortality among those with dementia.
Read More